Big Moves Ahead: Master Trust’s SEBI Filing Shakes Up Investment Scene

Supriya Lifescience Ltd, a prominent pharmaceutical manufacturer, has received a notice from the tax department demanding a total of ₹603.8 million. The notice arrives at a time when the company is experiencing strong operational momentum, with recent financial reports highlighting double-digit revenue and profit growth.

 

Key Highlights:

 

Significant Tax Demand: The tax department has issued a formal notice to Supriya Lifescience for a total demand of ₹603.8 million. The specific details or grounds for the demand have not been disclosed in the available sources, but such notices typically relate to assessments, disallowances, or compliance issues.

 

Financial Performance: Despite the tax setback, Supriya Lifescience reported a 16.4% year-on-year revenue increase for the quarter ended March 2025, reaching ₹184.1 crore. Profit after tax surged 36.4% to ₹50.4 crore, with margins improving to 36.7%.

 

Growth Outlook: The company remains optimistic about its future, with management projecting over 20% annual revenue growth and continued expansion in both domestic and international markets.

 

Operational Strength: Supriya Lifescience continues to invest in R&D and manufacturing capacity, maintaining a strong presence in the active pharmaceutical ingredients (API) sector with approvals from major global regulatory bodies.

 

No Immediate Impact on Operations: There is no indication that the tax notice will affect day-to-day operations or the company’s growth plans at this stage.

 

The company is expected to review the notice and determine its response, which may include legal or administrative remedies, as it continues to focus on its robust growth trajectory.

 

Sources: Business Standard, Trade Brains, India Infoline